BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
Want to see AU:BDX full AI Analyst Report?
Top Page
BCAL Diagnostics Limited
(Sydney:BDX)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.06
▼(-42.00% Downside)
Action:Downgraded
Date:06/17/26
The score is primarily weighed down by weak financial performance, including severe revenue contraction, large losses, and negative cash generation. Technical indicators also point to a bearish price trend, while valuation metrics are unfavorable due to losses (negative P/E).
Positive Factors
Proprietary diagnostic platform
BCAL's proprietary blood-based detection technology and laboratory diagnostics service constitute durable intellectual property and a platform business model. This supports recurring lab-service revenue, clinical integration with care pathways, and long-term differentiation in early cancer detection markets.
Negative Factors
Severe revenue contraction
A near-total collapse in revenue is a structural red flag: it erodes operating scale, undermines unit economics, and weakens the business case for continued investment. Recovering recurring lab volumes or market adoption will take sustained execution and time.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary diagnostic platform
BCAL's proprietary blood-based detection technology and laboratory diagnostics service constitute durable intellectual property and a platform business model. This supports recurring lab-service revenue, clinical integration with care pathways, and long-term differentiation in early cancer detection markets.
Read all positive factors
BCAL Diagnostics Limited (BDX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$25.44M
Dividend YieldN/A
Average Volume (3M)421.90K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS Growth26.04%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding368,683,300
10 Day Avg. Volume534,308
30 Day Avg. Volume421,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.64
Price to Sales (P/S)1047.06
P/FCF Ratio-3.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BCAL Diagnostics Limited Business Overview & Revenue Model
Company Description
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for ...
How the Company Makes Money
null...
BCAL Diagnostics Limited Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.31M | 21.64K | 3.10M | 2.79M | 718.67K | 275.25K |
| Gross Profit | 915.90K | 21.64K | 3.10M | 2.79M | 698.06K | 275.25K |
| EBITDA | -7.74M | -6.19M | -5.67M | -7.72M | -4.06M | -1.80M |
| Net Income | -7.16M | -7.24M | -6.40M | -5.06M | -3.39M | -1.52M |
Balance Sheet | ||||||
| Total Assets | 7.17M | 9.91M | 12.27M | 8.37M | 10.59M | 4.13M |
| Cash, Cash Equivalents and Short-Term Investments | 3.33M | 4.52M | 6.47M | 3.17M | 9.57M | 3.41M |
| Total Debt | 3.78M | 2.38M | 1.52M | 1.06M | 0.00 | 0.00 |
| Total Liabilities | 4.68M | 3.69M | 3.68M | 3.16M | 950.42K | 525.60K |
| Stockholders Equity | 2.50M | 6.22M | 8.59M | 5.21M | 9.64M | 3.61M |
Cash Flow | ||||||
| Free Cash Flow | -6.46M | -6.92M | -5.67M | -6.41M | -7.25M | -1.21M |
| Operating Cash Flow | -5.96M | -6.14M | -4.52M | -6.05M | -3.22M | -1.21M |
| Investing Cash Flow | -196.42K | -787.67K | -1.15M | 3.64M | -4.03M | -3.85K |
| Financing Cash Flow | 2.48M | 4.97M | 8.97M | 13.24K | 9.41M | 4.20M |
BCAL Diagnostics Limited Technical Analysis
Negative
0.10
Price Trends
0.08
Negative
0.10
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
20.80
Positive
28.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BDX, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and above the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 20.80 is Positive, neither overbought nor oversold. The STOCH value of 28.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BDX.
BCAL Diagnostics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$92.92M | -6.13 | -164.12% | ― | -14.85% | -41.04% | |
42 Neutral | AU$7.85M | -1.35 | 142.99% | ― | -100.00% | 68.62% | |
41 Neutral | AU$41.87M | -5.24 | -476.27% | ― | ― | -142.39% | |
40 Underperform | AU$25.44M | -3.12 | -164.22% | ― | ― | 26.04% | |
38 Underperform | AU$44.34M | -5.28 | -37.14% | ― | 4.66% | 12.39% |
* Healthcare Sector Average
AU:BDX
BCAL Diagnostics Limited
0.06
0.00
0.00%
AU:RHY
Rhythm Biosciences Ltd.
0.12
0.06
91.67%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.11
0.08
266.67%
AU:IBX
Imagion Biosystems Ltd.
0.02
<0.01
36.36%
AU:IIQ
Inoviq Ltd
0.38
-0.07
-14.77%
BCAL Diagnostics Limited Corporate Events
BCAL Moves Toward U.S. Entry With Sonic Healthcare Validation Deal
May 27, 2026
BCAL Diagnostics has signed a validation agreement with Sonic Healthcare USA to optimise and validate BreastestPlus Version 2 as a Laboratory Developed Test in a CLIA-certified reference laboratory in Austin, Texas. The collaboration targets entry...
BCAL taps industry veteran Anne-Louise Arnett to spearhead cancer diagnostics rollout
May 10, 2026
BCAL Diagnostics has appointed seasoned medical technology executive Anne-Louise (Annie) Arnett as chief executive officer from 1 June 2026, tasking her with accelerating the company’s commercial roadmap and international expansion. Arnett, ...
BCAL accelerates national rollout of cancer blood tests and prepares next-gen breast screening launch
Apr 21, 2026
BCAL Diagnostics reported progress on the national rollout of its Avantect pancreatic and ovarian blood tests, now available through Sonic Healthcare and Healius pathology networks, generating $88,000 in third-quarter revenue from 91 tests. A new ...
BCAL seeks Medicare backing for Avantect pancreatic cancer blood test
Mar 31, 2026
BCAL Diagnostics has lodged an application with the Medical Services Advisory Committee seeking Medicare Benefits Schedule reimbursement for its Avantect Pancreatic Cancer Test, aiming to make the blood-based assay more broadly accessible to high-...
BCAL speeds national rollout of Avantect cancer blood tests
Mar 25, 2026
BCAL Diagnostics has expanded national access to its Avantect pancreatic and ovarian early detection blood tests via selected Sonic Healthcare pathology centres in New South Wales, Victoria and Queensland, and through a new agreement with Healius ...
BCAL Director Jayne Shaw Increases Shareholding via On‑Market Purchase
Mar 20, 2026
BCAL Diagnostics has disclosed a change in the interests of director Jayne Shaw, who has increased her holding in the company through an on-market purchase. Shaw acquired 225,000 additional ordinary shares over 19–20 March 2026, paying $21,8...
BCAL Director Jayne Shaw Increases Shareholding Via On-Market Purchase
Mar 19, 2026
BCAL Diagnostics has reported a change in the interests of director Jayne Shaw, who has both direct and indirect holdings in the company’s securities. Through entities she controls and in her own name, Shaw maintains substantial share and op...
BCAL director Jayne Shaw boosts stake with on-market share purchase
Mar 17, 2026
BCAL Diagnostics director Jayne Shaw has increased her shareholding in the company through an on-market purchase of 300,000 ordinary shares on 16 March 2026, paying $29,251 for the stake. The transaction, made via entities she controls, lifts her ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.